

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POSITIVE PROFIT ALERT

ESTIMATED INCREASE IN PROFIT FOR THE INTERIM RESULTS OF 2013

This announcement is made by the Company pursuant to Part XIVA of the SFO and Rules 13.09(2) and 13.10B of the Listing Rules.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) hereby announces that, based on the preliminary estimates made by the Company, the Group’s net profit attributable to the parent company for the first half of 2013 is expected to increase by more than 40% as compared to the corresponding period of the previous year. This announcement is simultaneously released on the Shanghai Stock Exchange. The financial information referred to herein is only based on the preliminary estimates made by the Company and has not been audited. Detailed financial information of the Group will be disclosed in the 2013 interim report of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

The Board and all of its members hereby confirm that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept the responsibility for the truthfulness, accuracy and completeness of the contents of this announcement.

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (the “**SFO**”) and Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

1. ESTIMATED RESULTS FOR THE PERIOD

- (1) Period of the estimated results: 1 January 2013 to 30 June 2013.
- (2) Estimated results: Based on the preliminary estimates made by the financial department of the Company, the Group's net profit attributable to the parent company for the first half of 2013 is expected to increase by more than 40% as compared to the corresponding period of the previous year (which was disclosed in accordance with the relevant laws). Detailed financial information of the Group will be disclosed in the 2013 interim report of the Company.
- (3) The estimated results for the period have not been audited.

2. RESULTS OF THE CORRESPONDING PERIOD OF THE PREVIOUS YEAR

- (1) The Group's net profit attributable to the parent company: RMB701,766,957.49
- (2) Earnings per share: RMB0.37 (calculated based on the total share capital of 1,904,392,364 shares of the Company as at 30 June 2012)

3. MAJOR REASONS FOR THE ESTIMATED INCREASE IN PROFIT FOR THE PERIOD

The increase in the Group's net profit attributable to the parent company for the first half of 2013 is primarily due to (i) the steady growth maintained by the core businesses; and (ii) the gain on deemed disposal recognized from the dilution of equity interest resulting from the completion of placing of H shares of Sinopharm Group Co., Ltd.* (stock code: 01099), a company in which the Company has invested, in April 2013.

4. OTHER INFORMATION

The above estimated financial information is based on the preliminary estimates made by the Company. The detailed and precise financial information of the Group shall be based on the 2013 interim report which is to be officially disclosed by the Company. Investors are advised to be aware of the investment risks involved.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People's Republic of China
25 July 2013

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Zhang Guozheng, Mr. Wang Pinliang and Ms. Kang Lan; and the independent non-executive Directors are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

* for identification purposes only